These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 10657992)

  • 1. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria.
    Dunder U; Kaartinen V; Valtonen P; Väänänen E; Kosma VM; Heisterkamp N; Groffen J; Mononen I
    FASEB J; 2000 Feb; 14(2):361-7. PubMed ID: 10657992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspartylglycosaminuria: a review.
    Arvio M; Mononen I
    Orphanet J Rare Dis; 2016 Dec; 11(1):162. PubMed ID: 27906067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant glycosylasparaginase and in vitro correction of aspartylglycosaminuria.
    Mononen I; Heisterkamp N; Dunder U; Romppanen EL; Noronkoski T; Kuronen I; Groffen J
    FASEB J; 1995 Mar; 9(5):428-33. PubMed ID: 7896015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early initiation of enzyme replacement therapy improves metabolic correction in the brain tissue of aspartylglycosaminuria mice.
    Dunder U; Valtonen P; Kelo E; Mononen I
    J Inherit Metab Dis; 2010 Oct; 33(5):611-7. PubMed ID: 20607610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive neurodegeneration in aspartylglycosaminuria mice.
    Gonzalez-Gomez I; Mononen I; Heisterkamp N; Groffen J; Kaartinen V
    Am J Pathol; 1998 Oct; 153(4):1293-300. PubMed ID: 9777961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Massive accumulation of Man2GlcNAc2-Asn in nonneuronal tissues of glycosylasparaginase-deficient mice and its removal by enzyme replacement therapy.
    Kelo E; Dunder U; Mononen I
    Glycobiology; 2005 Jan; 15(1):79-85. PubMed ID: 15342551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mouse model for the human lysosomal disease aspartylglycosaminuria.
    Kaartinen V; Mononen I; Voncken JW; Noronkoski T; Gonzalez-Gomez I; Heisterkamp N; Groffen J
    Nat Med; 1996 Dec; 2(12):1375-8. PubMed ID: 8946839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction of peripheral lysosomal accumulation in mice with aspartylglucosaminuria by bone marrow transplantation.
    Laine M; Richter J; Fahlman C; Rapola J; Renlund M; Peltonen L; Karlsson S; Jalanko A
    Exp Hematol; 1999 Sep; 27(9):1467-74. PubMed ID: 10480438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice with an aspartylglucosaminuria mutation similar to humans replicate the pathophysiology in patients.
    Jalanko A; Tenhunen K; McKinney CE; LaMarca ME; Rapola J; Autti T; Joensuu R; Manninen T; Sipilä I; Ikonen S; Riekkinen P; Ginns EI; Peltonen L
    Hum Mol Genet; 1998 Feb; 7(2):265-72. PubMed ID: 9425233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspartylglycosaminuria: biochemistry and molecular biology.
    Aronson NN
    Biochim Biophys Acta; 1999 Oct; 1455(2-3):139-54. PubMed ID: 10571008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus-mediated gene transfer results in decreased lysosomal storage in brain and total correction in liver of aspartylglucosaminuria (AGU) mouse.
    Peltola M; Kyttälä A; Heinonen O; Rapola J; Paunio T; Revah F; Peltonen L; Jalanko A
    Gene Ther; 1998 Oct; 5(10):1314-21. PubMed ID: 9930336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aspartylglycosaminuria: protein chemistry and molecular biology of the most common lysosomal storage disorder of glycoprotein degradation.
    Mononen I; Fisher KJ; Kaartinen V; Aronson NN
    FASEB J; 1993 Oct; 7(13):1247-56. PubMed ID: 8405810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human leukocyte glycosylasparaginase: cell-to-cell transfer and properties in correction of aspartylglycosaminuria.
    Dunder U; Mononen I
    FEBS Lett; 2001 Jun; 499(1-2):77-81. PubMed ID: 11418116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of three alleles causing aspartylglycosaminuria: two from a British family and one from an American patient.
    Park H; Vettese MB; Fensom AH; Fisher KJ; Aronson NN
    Biochem J; 1993 Mar; 290 ( Pt 3)(Pt 3):735-41. PubMed ID: 8457202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dissection of the molecular pathology of aspartylglucosaminuria provides the basis for DNA diagnostics and future therapeutic interventions.
    Ikonen E; Syvänen AC; Peltonen L
    Scand J Clin Lab Invest Suppl; 1993; 213():19-27. PubMed ID: 8322015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single base deletion in exon 7 of the glycosylasparaginase gene causes a mild form of aspartylglycosaminuria in a patient of Mauritian origin.
    Park H; Rossiter M; Fensom AH; Winchester B; Aronson NN
    J Inherit Metab Dis; 1996; 19(1):76-83. PubMed ID: 8830180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzymatic diagnosis of aspartylglycosaminuria by fluorometric assay of glycosylasparaginase in serum, plasma, or lymphocytes.
    Mononen I; Mononen T; Ylikangas P; Kaartinen V; Savolainen K
    Clin Chem; 1994 Mar; 40(3):385-8. PubMed ID: 8131272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of nonviral promoters in adenovirus-mediated gene therapy: reduction of lysosomal storage in the aspartylglucosaminuria mouse.
    Virta S; Rapola J; Jalanko A; Laine M
    J Gene Med; 2006 Jun; 8(6):699-706. PubMed ID: 16518877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspartylglucosaminuria among Palestinian Arabs.
    Zlotogora J; Ben-Neriah Z; Abu-Libdeh BY; Sury V; Zeigler M
    J Inherit Metab Dis; 1997 Nov; 20(6):799-802. PubMed ID: 9427148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of deficient enzyme activity in a lysosomal storage disease, aspartylglucosaminuria, by enzyme replacement and retroviral gene transfer.
    Enomaa N; Danos O; Peltonen L; Jalanko A
    Hum Gene Ther; 1995 Jun; 6(6):723-31. PubMed ID: 7548272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.